论文部分内容阅读
根据目前临床使用的铂类抗癌药物的缺点和不足,作者报道了一种结构新颖的铂类配合物的合成方法,通过元素分析、质谱、红外和核磁共振氢谱等对合成物进行了结构表征,确认合成物为目标化合物。采用SRB比色法,测定该化合物对A549细胞及KB细胞的半数抑制浓度(IC50)分别为4.8mg/L和18.0mg/L。
According to the shortcomings and deficiencies of platinum anticancer drugs currently used clinically, the authors reported a novel method for the synthesis of platinum complexes by elemental analysis, mass spectrometry, infrared and nuclear magnetic resonance spectroscopy of the structure of the composition Characterization confirmed the compound as the target compound. The half-maximal inhibitory concentration (IC50) of this compound on A549 cells and KB cells was 4.8 mg / L and 18.0 mg / L, respectively, using SRB colorimetry.